Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.1 passage
• A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.1 passage
• A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus.1 passage
• A global scientific strategy to cure hepatitis B.1 passage
• A microbiota-centric view of diseases of the upper gastrointestinal tract.1 passage
• A model of the economic benefits of global hepatitis C elimination: an investment case.1 passage
• A non-endoscopic device to sample the oesophageal microbiota: a case-control study.1 passage
• A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.1 passage
• Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.1 passage
• Active observation versus interval appendicectomy after successful non-operative treatment of an appendix mass in children (CHINA study): an open-label, randomised controlled trial.1 passage
• Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass.1 passage
• Adjuvant1 passage
• Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.1 passage
• Advances in IgG4-related pancreatobiliary diseases.1 passage
• Advances in primary sclerosing cholangitis.1 passage
• Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial.1 passage
• An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.1 passage
• Anal cancer and precancerous lesions: a call for improvement.1 passage
• Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial.1 passage
• Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.1 passage
• Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.1 passage
• Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.1 passage
• Antifibrotics in chronic liver disease: tractable targets and translational challenges.1 passage
• Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.1 passage
• Artificial intelligence and computer-aided diagnosis in colonoscopy: current evidence and future directions.1 passage
• Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.1 passage
• Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.1 passage
• Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study.1 passage
• Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.1 passage
• Association between functional gastrointestinal disorders and migraine in children and adolescents: a case-control study.1 passage
• Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial.1 passage
• Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.1 passage
• Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.1 passage
• Beyond the Milan criteria for liver transplantation in children with hepatic tumours.1 passage
• Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.1 passage
• Bowel function after laparoscopic posterior sutured rectopexy versus ventral mesh rectopexy for rectal prolapse: a double-blind, randomised single-centre study.1 passage
• Breaking the therapeutic ceiling in drug development in ulcerative colitis.1 passage
• British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.1 passage
• Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial.1 passage
• COVID-19 as a barrier to attending for gastrointestinal endoscopy: weighing up the risks.1 passage
• Can immunosuppression be stopped after liver transplantation?1 passage
• Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.1 passage
• Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study.1 passage
• Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial.1 passage
• Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.1 passage
• Changes in colorectal cancer incidence in seven high-income countries: a population-based study.1 passage
• Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium.1 passage
• Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.1 passage
• Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial.1 passage
• Chronic constipation: new insights, better outcomes?1 passage
• Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England.1 passage
• Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.1 passage
• Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.1 passage
• Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial.1 passage
• Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.1 passage
• Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.1 passage
• Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials.1 passage
• Comorbidities in inflammatory bowel disease: a call for action.1 passage
• Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.1 passage
• Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.1 passage
• Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.1 passage
• Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis.1 passage
• Continuous wound infiltration versus epidural analgesia after hepato-pancreato-biliary surgery (POP-UP): a randomised controlled, open-label, non-inferiority trial.1 passage
• Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial.1 passage
• Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis.1 passage
• Current and emerging therapies for advanced biliary tract cancers.1 passage
• Current and potential treatments for primary biliary cholangitis.1 passage
• Cytomegalovirus infection associated with inflammatory bowel disease.1 passage
• DNA testing of pancreatic cyst fluid: is it ready for prime time?1 passage
• De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.1 passage
• Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.1 passage
• Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.1 passage
• Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand.1 passage
• Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.1 passage
• Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.1 passage
• Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study.1 passage
• Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study.1 passage
• Development and validation of a dynamic outcome prediction model for paracetamol-induced acute liver failure: a cohort study.1 passage
• Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.1 passage
• Diabetes following acute pancreatitis.1 passage
• Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.1 passage
• Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial.1 passage
• Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.1 passage
• Diagnostic yield of high-resolution manometry with a solid test meal for clinically relevant, symptomatic oesophageal motility disorders: serial diagnostic study.1 passage
• Differential diagnosis of inflammatory bowel disease: imitations and complications.1 passage
• Diffusion-weighted MRI in inflammatory bowel disease.1 passage
• Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.1 passage
• Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.1 passage
• Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.1 passage
• Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?1 passage
• Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.1 passage
• Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.1 passage
• Drug-induced liver injury in older people.1 passage
• Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.1 passage
• Early detection of pancreatic cancer.1 passage
• Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.1 passage
• Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study.1 passage
• Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life.1 passage
• Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.1 passage
• Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial.1 passage
• Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.1 passage
• Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa.1 passage
• Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.1 passage
• Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.1 passage
• Effects of enteral nutrition on gastrointestinal function in patients who are critically ill.1 passage
• Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.1 passage
• Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.1 passage
• Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.1 passage
• Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.1 passage
• Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.1 passage
• Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.1 passage
• Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.1 passage
• Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.1 passage
• Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.1 passage
• Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.1 passage
• Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial.1 passage
• Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.1 passage
• Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.1 passage
• Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis.1 passage
• Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.1 passage
• Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension.1 passage
• Emerging optical methods for endoscopic surveillance of Barrett's oesophagus.1 passage
• Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.1 passage
• Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial.1 passage
• Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.1 passage
• Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study.1 passage
• Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus.1 passage
• Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study.1 passage
• Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study.1 passage
• Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa.1 passage
• Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.1 passage
• Established and novel therapeutic options for autoimmune hepatitis.1 passage
• Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.1 passage
• Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.1 passage
• Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.1 passage
• Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.1 passage
• Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.1 passage
• Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.1 passage
• Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.1 passage
• Evidence of reducing ethanol content in beverages to reduce harmful use of alcohol.1 passage
• Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial.1 passage
• Factors affecting adenoma detection rate in a national flexible sigmoidoscopy screening programme: a retrospective analysis.1 passage
• Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.1 passage
• Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.1 passage
• Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.1 passage
• Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.1 passage
• Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial.1 passage
• FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.1 passage
• Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.1 passage
• Fully automated magnetically controlled capsule endoscopy for examination of the stomach and small bowel: a prospective, feasibility, two-centre study.1 passage
• Genetics of inflammatory bowel disease: beyond NOD2.1 passage
• Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.1 passage
• Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).1 passage
• Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.1 passage
• Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.1 passage
• Global hepatitis C elimination: an investment framework.1 passage
• Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies.1 passage
• Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.1 passage
• Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis.1 passage
• Global prevalence of hepatitis C virus in children in 2018: a modelling study.1 passage
• Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study.1 passage
• Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.1 passage
• Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.1 passage
• Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.1 passage
• Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.1 passage
• HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.1 passage
• Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial.1 passage
• Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.1 passage
• Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa.1 passage
• Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.1 passage
• Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.1 passage
• Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets.1 passage
• Hepatitis B virus infection in children and adolescents.1 passage
• Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.1 passage
• Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.1 passage
• Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.1 passage
• Hepatitis C treatment as prevention: evidence, feasibility, and challenges.1 passage
• Hepatitis C virus infection in children and adolescents.1 passage
• Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.1 passage
• Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.1 passage
• Home-based versus office-based biofeedback therapy for constipation with dyssynergic defecation: a randomised controlled trial.1 passage
• Human liver flukes.1 passage
• Idiopathic recurrent acute pancreatitis.1 passage
• Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.1 passage
• Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study.1 passage
• Improving the quality of surveillance colonoscopy in inflammatory bowel disease.1 passage
• Incidence and enteral feed antecedents of severe neonatal necrotising enterocolitis across neonatal networks in England, 2012-13: a whole-population surveillance study.1 passage
• Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study.1 passage
• Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.1 passage
• Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.1 passage
• Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions.1 passage
• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.1 passage
• Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.1 passage
• Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.1 passage
• Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.1 passage
• Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection?1 passage
• Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.1 passage
• Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.1 passage
• Laparoscopic versus open adhesiolysis for adhesive small bowel obstruction (LASSO): an international, multicentre, randomised, open-label trial.1 passage
• Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.1 passage
• Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.1 passage
• Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.1 passage
• Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.1 passage
• Liver disease in the young adult: the challenges and rewards.1 passage
• Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.1 passage
• Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral.1 passage
• Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.1 passage
• Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines.1 passage
• Liver transplantation in patients with alcohol-related liver disease: current status and future directions.1 passage
• Long-term challenges and perspectives of pre-adolescent liver disease.1 passage
• Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.1 passage
• Low-dose CT for the diagnosis of appendicitis in adolescents and young adults (LOCAT): a pragmatic, multicentre, randomised controlled non-inferiority trial.1 passage
• Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial.1 passage
• Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.1 passage
• Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.1 passage
• Management of hepatitis C virus infection in the Asia-Pacific region: an update.1 passage
• Management of metabolic syndrome and cardiovascular risk after liver transplantation.1 passage
• Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.1 passage
• Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement.1 passage
• Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective.1 passage
• Management of the multiple symptoms of irritable bowel syndrome.1 passage
• Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis.1 passage
• Mass migration to Europe: an opportunity for elimination of hepatitis B virus?1 passage
• Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease.1 passage
• Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.1 passage
• Microscopic colitis: pathophysiology and clinical management.1 passage
• Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Modifiable pathways for colorectal cancer: a mendelian randomisation analysis.1 passage
• Molecular endoscopy for targeted imaging in the digestive tract.1 passage
• Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.1 passage
• Molecular radionuclide imaging of pancreatic neoplasms.1 passage
• Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.1 passage
• Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.1 passage
• Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.1 passage
• Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.1 passage
• Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.1 passage
• Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.1 passage
• Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.1 passage
• Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.1 passage
• Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.1 passage
• Narcotic bowel syndrome.1 passage
• Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.1 passage
• Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial.1 passage
• New advances in the treatment of paediatric functional abdominal pain disorders.1 passage
• Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.1 passage
• Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.1 passage
• Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.1 passage
• Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.1 passage
• Non-alcoholic fatty liver disease and the interface between primary and secondary care.1 passage
• Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.1 passage
• Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis.1 passage
• Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis.1 passage
• Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.1 passage
• Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.1 passage
• Nutritional approaches for gastroparesis.1 passage
• Oesophageal dysphagia: a stepwise approach to diagnosis and management.1 passage
• Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.1 passage
• Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.1 passage
• Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.1 passage
• Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.1 passage
• Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.1 passage
• Optimal dilation time for combined small endoscopic sphincterotomy and balloon dilation for common bile duct stones: a multicentre, single-blinded, randomised controlled trial.1 passage
• Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.1 passage
• Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.1 passage
• Optimum timing of treatment for hepatitis C infection relative to liver transplantation.1 passage
• Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.1 passage
• Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.1 passage
• Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.1 passage
• Outpatient management of alcohol-related liver disease.1 passage
• Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.1 passage
• Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).1 passage
• Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.1 passage
• Pancreaticobiliary maljunction and congenital biliary dilatation.1 passage
• Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.1 passage
• Pathophysiology of irritable bowel syndrome.1 passage
• Pathophysiology, diagnosis, and management of opioid-induced constipation.1 passage
• Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.1 passage
• Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.1 passage
• Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.1 passage
• Perioperative lipid-enriched enteral nutrition versus standard care in patients undergoing elective colorectal surgery (SANICS II): a multicentre, double-blind, randomised controlled trial.1 passage
• Personalised medicine in Crohn's disease.1 passage
• Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.1 passage
• Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders.1 passage
• Place of death and factors associated with hospital death in patients who have died from liver disease in England: a national population-based study.1 passage
• Porto-sinusoidal vascular disease: proposal and description of a novel entity.1 passage
• Post-imaging colorectal cancer or interval cancer rates after CT colonography: a systematic review and meta-analysis.1 passage
• Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.1 passage
• Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.1 passage
• Precision medicine in pancreatic cancer: treating every patient as an exception.1 passage
• Predicting endoscopic activity recovery in England after COVID-19: a national analysis.1 passage
• Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.1 passage
• Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial.1 passage
• Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.1 passage
• Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis.1 passage
• Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.1 passage
• Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.1 passage
• Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.1 passage
• Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.1 passage
• Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.1 passage
• Prevention and treatment of nutritional complications after bariatric surgery.1 passage
• Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.1 passage
• Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.1 passage
• Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.1 passage
• Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial.1 passage
• Redefining fatty liver disease: an international patient perspective.1 passage
• Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.1 passage
• Research priority setting in Barrett's oesophagus and gastro-oesophageal reflux disease.1 passage
• Resolution of inflammation in inflammatory bowel disease.1 passage
• Resolving gastric cancer aetiology: an update in genetic predisposition.1 passage
• Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.1 passage
• Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.1 passage
• Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.1 passage
• Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis.1 passage
• Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study.1 passage
• Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis.1 passage
• Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies.1 passage
• Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.1 passage
• S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.1 passage
• SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.1 passage
• Safely reprocessing duodenoscopes: current evidence and future directions.1 passage
• Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.1 passage
• Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.1 passage
• Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.1 passage
• Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.1 passage
• Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.1 passage
• Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.1 passage
• Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.1 passage
• Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.1 passage
• Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.1 passage
• Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.1 passage
• Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.1 passage
• Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.1 passage
• Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.1 passage
• Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.1 passage
• Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.1 passage
• Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.1 passage
• Screening for liver fibrosis in the general population: a call for action.1 passage
• Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.1 passage
• Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.1 passage
• Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.1 passage
• Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.1 passage
• Shortening the duration of therapy for chronic hepatitis C infection.1 passage
• Significance of anti-HBc alone serological status in clinical practice.1 passage
• Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: a multicentre randomised controlled trial.1 passage
• Sleep and liver disease: a bidirectional relationship.1 passage
• Small molecule oral targeted therapies in ulcerative colitis.1 passage
• Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.1 passage
• Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.1 passage
• Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.1 passage
• Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.1 passage
• Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.1 passage
• Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.1 passage
• Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.1 passage
• Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial.1 passage
• Stigma and irritable bowel syndrome: a taboo subject?1 passage
• Stretching the boundaries for liver transplant in the 21st century.1 passage
• Submucosal surgery: novel interventions in the third space.1 passage
• Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial.1 passage
• Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial.1 passage
• Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial.1 passage
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.1 passage
• Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.1 passage
• Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure.1 passage
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.1 passage
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.1 passage
• The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.1 passage
• The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.1 passage
• The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited.1 passage
• The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.1 passage
• The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.1 passage
• The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial.1 passage
• The effect of sleep on gastrointestinal functioning in common digestive diseases.1 passage
• The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017.1 passage
• The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment.1 passage
• The intestinal microbiome and paediatric liver disease.1 passage
• The knowns and unknowns of treatment for alcoholic hepatitis.1 passage
• The mesentery: structure, function, and role in disease.1 passage
• The microbiota-gut-brain axis in obesity.1 passage
• The overlap between irritable bowel syndrome and organic gastrointestinal diseases.1 passage
• The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.1 passage
• The relationship between gastrointestinal cancers and the microbiota.1 passage
• The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.1 passage
• The role of the gut microbiota in sepsis.1 passage
• The shifting epidemiology of colorectal cancer in sub-Saharan Africa.1 passage
• Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease.1 passage
• Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.1 passage
• Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.1 passage
• Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.1 passage
• Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.1 passage
• Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development.1 passage
• Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.1 passage
• Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.1 passage
• Unmet needs and new models for future trials in autoimmune hepatitis.1 passage
• Update on the mesentery: structure, function, and role in disease.1 passage
• Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.1 passage
• Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis.1 passage
• Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.1 passage
• Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency.1 passage